HER2 targeting near-infrared photoimmunotherapy for a CDDP-resistant small-cell lung cancer.
Kazuomi TakahashiShunichi TakiHirotoshi YasuiYuko NishinagaYoshitaka IsobeToshinori MatsuiMisae ShimizuChiaki KoikeKazuhide SatoPublished in: Cancer medicine (2021)
In this study, we demonstrated that HER2 targeting NIR-PIT using trastuzumab is promising therapy for HER2-positive SCLC, and is more effective when HER2 expression is upregulated due to CDDP resistance, suggesting that the HER2 expression level positively corelated with the efficacy of NIR-PIT.